Adagio Therapeutics fetches $336m Series C

Adagio Therapeutics Inc, a developer of best-in-class antibodies to broadly neutralize coronaviruses, has closed $336 million in Series C financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this